| Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance H Hadeiba, K Lahl, A Edalati, C Oderup, A Habtezion, R Pachynski, ... Immunity 36 (3), 438-450, 2012 | 342 | 2012 |
| Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2 MH Kershaw, G Wang, JA Westwood, RK Pachynski, HL Tiffany, ... Human gene therapy 13 (16), 1971-1980, 2002 | 318 | 2002 |
| Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial P Sharma, RK Pachynski, V Narayan, A Fléchon, G Gravis, MD Galsky, ... Cancer cell 38 (4), 489-499. e3, 2020 | 263 | 2020 |
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies HE Kohrt, R Houot, MJ Goldstein, K Weiskopf, AA Alizadeh, J Brody, ... Blood, The Journal of the American Society of Hematology 117 (8), 2423-2432, 2011 | 258 | 2011 |
| Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study MJ Morris, SP Rowe, MA Gorin, L Saperstein, F Pouliot, D Josephson, ... Clinical Cancer Research 27 (13), 3674-3682, 2021 | 249 | 2021 |
| Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy MP Chao, C Tang, RK Pachynski, R Chin, R Majeti, IL Weissman Blood, The Journal of the American Society of Hematology 118 (18), 4890-4901, 2011 | 225 | 2011 |
| Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment JL Gulley, RA Madan, R Pachynski, P Mulders, NA Sheikh, J Trager, ... JNCI: Journal of the National Cancer Institute 109 (4), djw261, 2017 | 192 | 2017 |
| Secondary lymphoid-tissue chemokine (SLC) stimulates integrin α4β7-mediated adhesion of lymphocytes to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) under flow RK Pachynski, SW Wu, MD Gunn, DJ Erle The Journal of Immunology 161 (2), 952-956, 1998 | 179 | 1998 |
| The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses RK Pachynski, BA Zabel, HE Kohrt, NM Tejeda, J Monnier, CD Swanson, ... Journal of Experimental Medicine 209 (8), 1427-1435, 2012 | 174 | 2012 |
| Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ... The lancet oncology 20 (4), 581-590, 2019 | 155 | 2019 |
| Structure-function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM-1. M Tidswell, R Pachynski, SW Wu, SQ Qiu, E Dunham, N Cochran, ... Journal of immunology (Baltimore, Md.: 1950) 159 (3), 1497-1505, 1997 | 118 | 1997 |
| Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). P Sharma, RK Pachynski, V Narayan, A Flechon, G Gravis, MD Galsky, ... Journal of Clinical Oncology 37 (7_suppl), 142-142, 2019 | 112 | 2019 |
| Presentation of integrins on leukocyte microvilli: a role for the extracellular domain in determining membrane localization MA Abitorabi, RK Pachynski, RE Ferrando, M Tidswell, DJ Erle The Journal of cell biology 139 (2), 563-571, 1997 | 104 | 1997 |
| Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness Y Li, TSM Lih, SM Dhanasekaran, R Mannan, L Chen, M Cieslik, Y Wu, ... Cancer Cell 41 (1), 139-163. e17, 2023 | 65 | 2023 |
| Mechanisms and functions of chemerin in cancer: potential roles in therapeutic intervention WJ Shin, BA Zabel, RK Pachynski Frontiers in immunology 9, 2772, 2018 | 62 | 2018 |
| Chemerin suppresses breast cancer growth by recruiting immune effector cells into the tumor microenvironment RK Pachynski, P Wang, N Salazar, Y Zheng, L Nease, J Rosalez, ... Frontiers in immunology 10, 983, 2019 | 56 | 2019 |
| Abstract CT116: BMS-986205, an optimized indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination … LL Siu, K Gelmon, Q Chu, R Pachynski, O Alese, P Basciano, J Walker, ... Cancer Research 77 (13_Supplement), CT116-CT116, 2017 | 56 | 2017 |
| Chemerin reactivates PTEN and suppresses PD-L1 in tumor cells via modulation of a novel CMKLR1-mediated signaling cascade K Rennier, WJ Shin, E Krug, G Virdi, RK Pachynski Clinical cancer research 26 (18), 5019-5035, 2020 | 52 | 2020 |
| Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer D Bansal, MA Reimers, EM Knoche, RK Pachynski Cancers 13 (2), 334, 2021 | 51 | 2021 |
| IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) RK Pachynski, C Morishima, R Szmulewitz, L Harshman, L Appleman, ... Journal for ImmunoTherapy of Cancer 9 (8), 2021 | 49 | 2021 |
Jeff MichalskiWashington University在 wustl.edu 的电子邮件经过验证
